Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 2008 April 22; 98(8): 1366–1379.
Published online 2008 March 18. doi:  10.1038/sj.bjc.6604308
PMCID: PMC2361696

VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy


Bevacizumab, an anti-vascular endothelial growth factor (VEGF-A) antibody, is used in metastatic colorectal carcinoma (CRC) treatment, but responses are unpredictable. Vascular endothelial growth factor is alternatively spliced to form proangiogenic VEGF165 and antiangiogenic VEGF165b. Using isoform-specific enzyme-linked immunosorbent assay and quantitative polymerase chain reaction, we found that over 90% of the VEGF in normal colonic tissue was VEGFxxxb, but there was a variable upregulation of VEGFxxx and downregulation of VEGFxxxb in paired human CRC samples. Furthermore, cultured colonic adenoma cells expressed predominantly VEGFxxxb, whereas colonic carcinoma cells expressed predominantly VEGFxxx. However, adenoma cells exposed to hypoxia switched their expression from predominantly VEGFxxxb to predominantly VEGFxxx. VEGF165b overexpression in LS174t colon cancer cells inhibited colon carcinoma growth in mouse xenograft models. Western blotting and surface plasmon resonance showed that VEGF165b bound to bevacizumab with similar affinity as VEGF165. However, although bevacizumab effectively inhibited the rapid growth of colon carcinomas expressing VEGF165, it did not affect the slower growth of tumours from colonic carcinoma cells expressing VEGF165b. Both bevacizumab and anti-VEGF165b-specific antibodies were cytotoxic to colonic epithelial cells, but less so to colonic carcinoma cells. These results show that the balance of antiangiogenic to proangiogenic isoforms switches to a variable extent in CRC, regulates tumour growth rates and affects the sensitivity of tumours to bevacizumab by competitive binding. Together with the identification of an autocrine cytoprotective role for VEGF165b in colonic epithelial cells, these results indicate that bevacizumab treatment of human CRC may depend upon this balance of VEGF isoforms.

Keywords: bevacizumab, VEGF, VEGF165b, biomarker, angiogenesis, colon carcinoma

Solid tumour growth is dependent on the induction of their own blood supply by inducing a proangiogenic state in the tissue environment, regulating this balance between proangiogenic growth factors and antiangiogenic inhibitors (Folkman, 1985, 1995; Boehm et al, 1997). One growth factor that has been shown to be an effective target for antiangiogenic therapy (AAT) is vascular endothelial growth factor-A (VEGF-A). Inhibition of VEGF by humanised monoclonal antibodies has been shown to be effective in increasing the median survival in metastatic colorectal cancer (CRC) when combined with chemotherapy (Hurwitz et al, 2004).

Vascular endothelial growth factor-A is generated by alternative splicing from eight exons within the VEGF-A gene. All isoforms contain exons 1–5 and the terminal exon, exon 8. Exons 6 and 7, which encode heparin-binding domains, can be included or excluded. This gives rise to a family of proteins termed according to their amino-acid number, VEGF165, VEGF121, VEGF189 and so on. Exon 8, however, contains two 3′ splice sites in the nucleotide sequences, which can be used by the cell to generate two families of isoforms with identical length, but differing C-terminal amino-acid sequences (Bates et al, 2002). VEGFxxx, the proangiogenic family of isoforms, is generated by use of the most proximal sequence in exon 8 (resulting from inclusion of exon 8a). The more recently described VEGFxxxb isoforms are generated by the use of a distal splice site, 66 bp further along the gene from the proximal splice site. This results in splicing out of exon 8a and the production of mRNA sequences that encode the VEGFxxxb family (Bates et al, 2002). The two resultant families of proteins are of the same length, but with different carboxyl termini. VEGF165b was the first of these exon 8b-encoded isoforms identified and subsequent studies demonstrated the existence of VEGF121b, VEGF183b, VEGF145b (Perrin et al, 2005) and VEGF189b (Miller-Kasprzak and Jagodzinski, 2008).

The functional consequences of this altered C terminus are that VEGF165b homodimers compete with VEGF165 homodimers for binding to their principal receptor, VEGFR-2, at a one-to-one ratio and inhibit endothelial cell proliferation and migration in culture (Woolard et al, 2004; Cebe Suarez et al, 2006). VEGF165b blocks VEGF165-driven angiogenesis in vivo in the rabbit, rat (Woolard et al, 2004), mouse and chick (Cebe Suarez et al, 2006), and human malignant melanomas consisting of cells overexpressing VEGF165b and cells expressing VEGF165 grow slower in nude mice than those consisting of cells expressing VEGF165 alone. Recombinant human VEGF165b is also antiangiogenic in hypoxia-driven angiogenesis in the eye (Konopatskaya et al, 2006).

Although VEGF has been shown to be critical in CRC by inhibition studies, the expression of VEGF in CRC has not been investigated using tools that distinguish between the proangiogenic VEGFxxx isoforms and the antiangiogenic VEGFxxxb isoforms. The vast majority of studies have measured total VEGF levels in plasma, tumours or serum using commercially available antibodies that do not distinguish between pro- and antiangiogenic isoforms, as commercial enzyme-linked immunosorbent assays (ELISAs) detect VEGFxxxb isoforms. Furthermore, it is not known whether the VEGFxxxb isoforms are able to slow or reduce tumour growth if they are highly expressed. To determine whether this antiangiogenic isoform family is expressed in CRC, and how that expression may be regulated, this study compares the balance of expression of the VEGFxxxb family of isoforms in human CRC with paired normal colonic mucosa samples and show how the expression of VEGFxxxb and VEGFxxx is altered during the malignant transformation of colonic adenoma cells in vitro. Furthermore, to determine whether this balance has the potential to regulate tumour growth rates, we have measured VEGF165b functional effects on colon carcinoma growth in animal models where the tumour growth was VEGF-dependent. Furthermore, we assess whether bevacizumab either specifically binds VEGFxxx (proangiogenic) isoforms, or also has cross-reactivity with antiangiogenic VEGF165b and whether it inhibits VEGF165b-expressing tumours.


Human tissue samples

Paired colon samples were from partial colon resection for carcinoma. Samples were obtained by taking biopsies of the fresh specimen from a nonnecrotic central portion of the tumour and from a peripheral part of the macroscopically normal colonic epithelium (n=18 pairs). Samples were collected with Local Ethics committee approval. The mean patient age was 71.5 (range 58–80) years, with 62% male subjects and Duke's staging as follows: 6.7% A, 46.7% B and 46.7% C. Biopsies were immediately frozen in liquid nitrogen and then stored at −80°C until processed. Biopsies were frozen in liquid nitrogen again immediately prior to manual slicing with a sterile blade. The mass of each tissue was recorded, and samples were homogenised and mRNA and protein extracted as described below.

Expression analysis

For each of eight pairs of samples, mRNA was extracted from approximately 200 mg of tissue (Chomczynski and Sacchi, 1987) and reverse transcribed as previously described (Bates et al, 2002). The cDNA was amplified using primers complementary to VEGF exon 7 and the 3′-UTR downstream of exon 8b, as previously described (Bates et al, 2002). The products were subjected to standard agarose gel electrophoresis and ethidium bromide staining. Protein was extracted from approximately 250 mg tissue, from 18 pairs of samples, resolved by 12% sodium dodecyl sulphate-polyacrylamide gel electrophoresis, transferred and immunoblotted as previously described (Woolard et al, 2004). Briefly, membranes containing recombinant human VEGF165 and/or VEGF165b protein (50 ng of each) and protein samples extracted from colon (100 μg of each) were probed with mouse anti-VEGFxxxb IgG (2 μg ml−1 A56/1; R&D Systems, cat no. MAB3045) (Woolard et al, 2004) or rabbit anti-VEGF IgG (1 μg ml−1 A-20; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and detected with horseradish peroxidase-conjugated stabilised goat anti-mouse or anti-rabbit IgG (1/7000; Pierce Biotechnology, Rockford, IL, USA). Visualisation of protein bands was achieved with SuperSignal West Femto Maximum Sensitivity Substrate Kit (Pierce Biotechnology).

Quantitative RT-PCR

Quantitative PCR assays were carried out on cDNA generated as above. An exon 7b forward primer and a 3′-UTR primer (both pan-VEGF quantitative polymerase chain reaction (Q-PCR) from Primer Design, Southampton, UK) or an exon 7a forward primer 5′-TTGCTCAGAGCGGAGAAAGC-3′and a reverse primer specific for exon 8a that did not detect VEGFxxxb isoforms 5′-TCACCGCCTCGGCTTGTCACAT-3′ were used. Reactions were performed using a SmartCyclerII (Cepheid, Sunnyvale, CA, USA) q-PCR machine, with 25 μl reaction volumes comprising 12.5 μl Quantitect SYBRgreen 2 × master mix (Qiagen, Crawley, UK), 1 μl cDNA and 1 μl primer mix cycled at 95°C for 15 min followed by 50 cycles of 60°C for 30 s, 72°C for 60 s, 79°C for 15 s (reading) and 95°C for 30 s. A melt curve was then performed by ramping the temperature from 60 to 95°C at 0.2°C per second, reading throughout. DNA standards used were VEGF165b or VEGF165 cloned into pcDNA3, or oligonucleotides containing the full sequence between the primers (Primer Design).

Figures 1A and B show examples of the reverse transcription-polymerase chain reaction (RT-PCR) curves for VEGF165b and VEGF165 templates respectively using pan-VEGF primers. Figure 1C shows the standard curve generated from cycle threshold for the two templates, showing that there was no difference in the standard curves (n=3). Thus the efficiency of amplification of the two templates is not different. Figure 1D shows the amplification curves for the exon 8a primers using the VEGF165 sequence as a template (VEGF165b template did not result in amplification until 18 cycles later than equivalent VEGF165 concentration). Total VEGF and VEGFxxx copy numbers were calculated for each sample using the calibration curve shown in Figure 1E. The difference between the total VEGF and the VEGFxxx copy number was assumed to be the VEGF165b copy number.

Figure 1
Quantification of mRNA expression of pan-VEGF and VEGFxxx isoform mRNA by Q-PCR. (A and B) Primers that detected all isoforms were used to detect increasing amounts of VEGF165b (A) or VEGF165 (B). (C) Standard curves for the two isoforms were the same ...


Immunohistochemistry was performed on formalin-fixed paraffin-embedded normal colonic mucosa, obtained with local ethics committee approval from archival material as previously described (Woolard et al, 2004). Sections were stained with either mouse monoclonal anti-VEGFxxxb IgG (8 μg ml−1; R&D Systems, cat no. MAB3045) or 5 μg ml−1 mouse anti-VEGF IgG (Santa Cruz; SC-7269) or a normal mouse IgG (Sigma Aldrich, Gillingham, UK; I8765), as a negative control.


pan-VEGF mouse capture antibody (0.1 μg) (Duoset VEGF ELISA DY-293; R&D Systems, Minneapolis, MN, USA) diluted in 1 × phosphate-buffered saline (PBS) (pH 7.4) was adsorbed onto each well of a 96-well sterile plate (Immulon 2HB Thermo Life Sciences, Basingstoke, UK) or, for the VEGFxxxb ELISA, 0.08 μg AF293-NA Goat anti-VEGF polyclonal IgG (R&D Systems), overnight at room temperature. The plates were washed three times between each step with 1 × PBS-Tween (0.05%). After blocking with bovine serum albumin in PBS for 30 min at 37°C, recombinant human VEGF165 standards or VEGF165b (R&D Systems) diluted in blocking solution (ranging from 62.5 pg ml−1 to 2 ng ml−1) or protein sample was added to each well. After incubation for 30 min at 37°C with shaking and three washes, 100 μl of biotinylated goat anti-human VEGF (50 ng ml−1 in blocking solution; R&D Systems) or a mouse monoclonal anti-VEGFxxxb-biotinylated IgG (clone 264610/1; R&D Systems) at 0.4 μg ml−1 was added to each well, and plates left for 30 min at 37°C with shaking. Streptavidin-HRP (100 μl) (R&D Systems) at 1 : 200 dilution in PBS was added, plates left at room temperature for 20 min and 100 μl per well O-phenylenediamine dihydrochloride solution (Substrate reagent pack DY-999; R&D Systems) added, protected from light and incubated for 20 min at room temperature. The reaction was stopped with 100 μl per well 1 mol l−1 H2SO4 (10276; BDH Chemicals, Poole, UK), and absorbance read immediately in an Opsys MR 96-well plate reader (Dynex Technologies, Chantilly, VA, USA) at 492 nm, with control reading at 460 nm.

Characterisation of the ELISA

We used both this antibody (MAB3045) and a separate antibody generated against the terminal nine amino acids of VEGF165b, raised by R&D Systems and biotinylated (clone 264610/1), to quantitate the relative levels of VEGF165b. Both VEGF165b antibodies were as sensitive as the commercially available VEGF ELISA (see Figure 2A). The biotinylated 264610/1 antibody specifically detects VEGF165b, is accurate down to below 62.5 pg ml−1 VEGF165b and does not detect VEGF165, even at 4 ng ml−1 in an ELISA (Figure 2B). Both antibodies were used to determine the amount of VEGFxxxb in human tissues from pancreatic islets, placenta, lung, colon and prostate. The two ELISAs did not differ in their results (e.g., colon tissue, 130±40 pg mg−1 MAB3045 ELISA 128±20 pg mg−1 clone 264610/1 ELISA, N=18). The biotinylated 264610 ELISA was used to quantitate the amount of VEGF in tissue samples, as it was more sensitive, a simpler procedure, could use commercially available capture antibodies and the protocol was most comparable to the commercial VEGF DuoSet ELISA. To determine whether VEGF165 could interfere with this VEGF165b ELISA, serial dilutions of rhVEGF165 were assayed. As seen in Figure 2B, there was no significant change in OD values by the addition of rhVEGF165 as high as 4000 pg ml−1, indicating that the VEGFxxxb ELISA specifically detects VEGF165b, and is not affected by the conventional VEGF isoform, VEGF165.

Figure 2
Quantification of VEGFxxxb protein expression by ELISA. (A) Sensitivity of VEGF165b-specific antibody 264610/1 was determined using a sandwich ELISA. Increasing concentrations of VEGF165b (for clone 264610/1 and MAB3045) or VEGF165 (for R&D DuoSet, ...

To determine whether commercially available ELISAs also detected VEGF165b, we carried out a VEGF ELISA using increasing concentrations of VEGF165b. Figure 2C shows that increasing concentrations of VEGF165b were detected by the R&D Duoset kit – the most widely used ELISA. Interestingly, this ELISA detects VEGF165b at a lower affinity than VEGF165. The ratio of the slopes is 0.42±0.004 or 42±0.4%. To confirm this, we used VEGF165b generated from two different sources – R&D Systems and an in-house production (both proteins were quantitated by Bradford Assay). The R&D Duoset Kit (DY293B) is a second generation ELISA introduced in 2004. We are unaware of published information on sFlt-1 interference in the current DuoSet kit. Figure 2C shows that increasing concentrations of sFlt-1 did not affect the pan-VEGF ELISA at least up to 2000 pg ml−1 VEGF.

With the previous ELISA, VEGF165b levels were detected at 100% of VEGF165, indicating that the previous ELISA kit had the same affinity for both isoforms. To ensure that this was due to a difference in affinity of the antibodies for the two isoforms, we carried out surface plasmon resonance analysis of binding coefficients.

Surface plasmon resonance

To compare the binding affinities of VEGF165 and VEGF165b to the pan-VEGF antibody used in the R&D Duoset detection kit, we amine-coupled the latter to a CM5 sensor chip (Biacore AB, Uppsala, Sweden) to an immobilisation level of 630 response units (RU). To compare the binding affinities of VEGF165 and VEGF165b to bevacizumab, the latter was amine-coupled to a CM5 sensor chip (Biacore AB) to an immobilisation level of 580 RU. The coupling was performed using EDC/NHS and 1 mol l−1 ethanolamine (Biacore) as per the manufacturer's instructions, with the bevacizumab dissolved in 10 mmol l−1 sodium acetate (pH 4.5). A blank reference cell was formed by the same activation and deactivation process involved in amine coupling without adding antibody. Samples containing VEGF165 or VEGF165b diluted in HBS-EP sample buffer (Hepes-buffered saline with EDTA and P20 surfactant, Biacore AB) were then run at twofold serial dilutions from 180 nmol l−1 down, in random order in duplicate. Injection was performed at 30 μl min−1 for 3 min, followed by 6 min of buffer only, for monitoring of dissociation. Regeneration between each interaction was performed by injection of 4 mol l−1 MgCl2 at 20 μl min−1 for 40 s, followed by a 2-min period of stabilisation before the next injection. Figure 3A shows the binding curves of VEGF165 to the RnD detection antibody and Figure 3B shows binding of VEGF165b to the same antibody. The RnD detection antibody had a higher association coefficient for VEGF165 than VEGF165b and a lower dissociation coefficient for VEGF165 than VEGF165b (Figure 3C), resulting in an affinity of 602 pM for VEGF165, but 3.98 nM for VEGF165b, an ~6.6-fold difference in affinity, indicating that the underestimation of the commercial ELISA for VEGF165b was due to a difference in affinity for the antigen.

Figure 3
The commercially available VEGF antibody has a lower affinity for VEGF165b than VEGF165. The mouse detection antibody from the R&D ELISA Duoset was immobilised on a sensor chip, and VEGF isoforms allowed to flow over the detecting chip. (A) VEGF ...

The actual VEGF concentrations (VEGFtotal) in human tissue are the sum of VEGFxxx and VEGFxxxb.

equation image

The commercially available pan-VEGF ELISA has a lower affinity for VEGF165b than for VEGF165 by 42%. Therefore the measured VEGF levels (VEGFmeasured) in the commercially available ELISA are the sum of VEGF165 and 42% of VEGF165b.

equation image

equation image

We used the above correction to estimate tissue concentration of VEGFxxxb and its relative proportion of total VEGF.

Adenoma-carcinoma cell VEGF expression

Colonic adenoma cells (AAC1) and their in vitro-derived carcinoma cells (10C) were kindly donated by Professor C Paraskeva (Williams et al, 1990). The adenoma cells are a non-tumour-forming clonogenic variant of the PC/AA cell line derived from a polyp from a patient with familial adenoma polyposis (Paraskeva et al, 1988). The cells were cultured to 100% confluence in Dulbecco's modified Eagle's medium supplemented with 20% fetal bovine serum, 1% penicillin/streptomycin and 0.2% Actrapid insulin (Novo Nordisk, Crawley, UK). Protein was extracted from confluent cells in fresh media as above cells were placed in a hypoxic chamber (Billups-Rothenburg, Del Mar, CA, USA) for 5 min at 20 l min−1 with 5% CO2/nitrogen gas mixture (BOC) and incubated at 37°C. The gas was changed twice per day.

In vivo tumour model

LS174t human colon carcinoma cell lines were used (ECACC, Salisbury, UK) (Yuan et al, 1996; Lee et al, 2000). Cells were transfected with 1 μg of purified plasmid pcDNA3 either as empty vector, with VEGF165, VEGF165b, or both VEGF165 and VEGF165b vectors, using Lipofectamine Plus (Invitrogen, Carlsbad, CA, USA) as per the manufacturer's instructions. Cells were selected using geneticin (500 μg ml−1). Conditioned media were analysed by ELISAs for VEGF and VEGFxxxb production per cell per 24 h, to confirm expression levels of VEGF isoforms. A total of 2 × 106 cells were injected subcutaneously into the lumbar region of nude mice (six per group unless otherwise stated). Mice were then monitored every 2–3 days and tumour length and width measured. When the first tumour reached 16 mm in maximum diameter, all mice were killed. Tumour volumes were calculated according to the formula (length × width × (length+width)/2). Injections, measurements and analysis were all carried out with the investigators blinded to group.


Measurement of the cell-cytotoxicity effects of blocking VEGF isoforms was performed using a lactate dehydrogenase (LDH) assay following exposure of the cells to various antibodies and RTKIs as described in the results. Cells were grown to 90–100% confluence in 96-well plates prior to treatment in serum-free medium, against which treatment was compared. A Cytotox 96 Non-Radioactive Cytotoxicity Assay (Promega Corp, Madison, WI, USA, no. G1780) was used according to the manufacturer's instructions.


Means and standard errors are given unless stated otherwise. Tumour volumes, cell cycle parameters and apoptosis were compared by one-way analysis of variance (ANOVA) followed by a Bonferroni post-hoc test. Tumour growth curves were fitted by nonlinear regression using an exponential curve fit in Prism. Doubling times were calculated from 0.69 k−1, and are given as mean (95% confidence intervals (CI)), and curve-fitting parameters compared using an F-test. Analysis of ELISA results was performed using Wilcoxon's signed matched ranks at 95% significance level (two-tailed).


Normal colonic epithelial cells and colonic carcinomas expressed VEGF165b mRNA

To determine whether VEGF165b and VEGF165 mRNA were expressed in normal and cancerous colon, RT-PCR using primers that distinguish between the two families of isoforms was carried out on eight pairs of samples. Reverse transcription-polymerase chain reaction gave two bands, one at ~135 bp, consistent with VEGF165b or VEGF189b, and one at ~200 bp, consistent with VEGF165 and VEGF189. This size difference was due to the splicing out of exon 8a in the VEGFxxxb family, resulting in the shorter mRNA (although exon 8b is present in the mRNA of the VEGFxxx family, a stop codon in exon 8a prevents its translation). VEGFxxx and VEGFxxxb mRNA expression was detected in both normal and tumour tissue (Figure 4A).

Figure 4
VEGF165b mRNA is expressed in human colon tissue and colon cancer. (A) VEGFxxxb mRNA is expressed in normal and cancerous colon. PCR of cDNA reverse transcribed from RNA extracted from paired human colon samples shows two bands, the proximal splice isoforms ...

VEGF mRNA is differentially spliced in colon cancer

Quantitative PCR on mRNA extracted from seven pairs of colorectal normal and tumour tissue demonstrated that the VEGFxxx mRNA copy number was only 9.1±2.8% of the total VEGF level in normal tissues, indicating that VEGFxxxb species form more than 90% of the mRNA. There was an increase in copy number of all VEGF isoforms from 5±2.2 to 11±3.5 × 103 copies per μg of tissue (Figure 4B). This upregulation was specific for the VEGF165 isoform (0.18±0.32 to 6.0±2.6 × 103 copies per μg, Figure 4C, P<0.01, ANOVA), and not for the VEGF165b isoform (4.8±2.2 to 5.6±2.0 × 103 copies per μg, Figure 4D), such that in cancers, 45±13% of the VEGF mRNA was VEGF165.

VEGF165b and VEGF121b protein are expressed in normal and cancerous colon

To determine whether protein expression of VEGFxxxb isoforms was present in normal and tumour tissues, western blotting and ELISA were carried out using antibodies specific to VEGF165b and antibodies that do not distinguish between isoforms. The previously characterised anti-VEGF165b antibody (R&D Systems, cat no. MAB3045) demonstrates highly specific binding to recombinant human VEGF165b but not to recombinant human VEGF165 (Pritchard-Jones et al, 2007). Figure 5A shows that both VEGF121b and VEGF165b were expressed in both normal colonic mucosa and in carcinomas as detected by western blotting. To determine which cells in colonic epithelium expressed the VEGFxxxb isoforms, we used immunohistochemistry to stain the normal colon samples. Figure 5B shows that VEGFxxxb was highly expressed in colonic epithelial cells of the brush border (especially cells at the apex of the villi), cells within the lamina propria with plasma cell morphology and goblet cells. Staining of sections with the VEGF antibody that recognises all VEGF isoforms (including VEGFxxxb isoforms, Figure 5C) showed that VEGF was expressed in all the places where VEGF165b staining was apparent. Nonspecific isotype control IgG did not stain (Figure 5D).

Figure 5
VEGFxxxb is the predominant family of VEGF proteins in normal colon but not in colon cancer. (A) Western blots of VEGFxxxb expression in normal and cancerous colon. Two strong bands are seen in each tissue, consistent with VEGF165b and VEGF121b. Longer ...

Increased VEGF protein levels in cancer are restricted to the angiogenic isoforms

To determine whether the previously reported increase in VEGF expression (Ellis et al, 2000; Reinmuth et al, 2003) in CRC was due to changes in VEGFxxxb or VEGFxxx, the levels of VEGF and VEGFxxxb were determined by ELISA and isoform-specific ELISA respectively. Total VEGF was significantly upregulated in CRC (288±48 pg VEGF per mg total protein) compared to normal colon (122±23 pg mg−1, n=18; P<0.01, Wilcoxon Figure 5E). VEGFxxxb concentrations, however, were no different in tumour extracts (160±50 pg mg−1) than in controls (130±23 pg mg−1; P=0.96, Figure 5F). Since the total VEGF is the sum of the pro- and antiangiogenic isoforms, the level of VEGFxxx expression was calculated in these samples. The mean VEGFxxx concentration in normal mucosa was not significantly different from zero. In CRC tissue, however, the mean VEGFxxx level was 128±53 pg per mg total protein, indicating that the difference in total VEGF expression was due to an upregulation in VEGFxxx production alone. Thus, there was a shift from predominantly VEGFxxxb protein in controls to VEGFxxx in CRC (mean±s.e.m. ratio VEGFxxxb/total VEGF: 112±12% in controls, 59±12% in tumours; P<0.001 paired t-test). Figure 5G shows that the ratio of VEGFxxx to VEGFxxxb in the tumours was highly variable with some patients having no excess of VEGFxxx, and others up to 57-fold excess of VEGFxxx. There was no relationship between Dukes' staging and VEGFxxxb concentration or proportion (P=0.75; one-way ANOVA, data not shown).

The switch in expression is part of the malignant transformation program

As VEGF expression is predominantly proangiogenic in CRC and predominantly antiangiogenic in normal colonic epithelium, cell lines at different stages of the malignant transformation may reflect this. Cells along the adenoma-carcinoma sequence, grown in 100% confluent monolayers, were assayed for VEGF expression as shown in Figure 6. Although the total VEGF expression increased along the adenoma-carcinoma sequence, the degree to which it did so was very variable (Figure 6A) and only the LS174t cells demonstrated a significant such increase. In addition, the VEGFxxxb expression was reduced in the carcinoma cells compared to the adenoma cells, but this only reached significance in the HT29 cell line (Figure 6B). Overall, the effect of a shift from anti- to proangiogenic VEGF expression predominance in CRC cell lines was due to a combination of reduced VEGFxxxb expression and increased VEGFxxx expression, resulting in a shift from 82±10% VEGFxxxb in adenoma cells to between 5.7±0.3 and 53±5.8% in the carcinoma cell lines (P<0.0001, one-way ANOVA, Figure 6C). There was thus a predominance of VEGFxxxb in this adenoma cell line, and a variable switch towards predominance of VEGFxxx in the colonic carcinoma cell lines.

Figure 6
Vascular endothelial growth factor balance shifts from anti- to proangiogenic along the adenoma-carcinoma sequence in vitro. HT29, LS174t and 10C well-differentiated adenocarcinoma cell lines and the 10C parent, AAC1 adenoma cell line, were grown to 100% ...

To test whether hypoxic upregulation of VEGF expression induced a switch in the relative expression of pro- and antiangiogenic VEGF required the use of cell lines that produced predominantly VEGFxxxb in normoxia, such as AAC1 and 10C. The exposure of the AAC1 cells to hypoxia resulted in a switch from predominantly antiangiogenic VEGFxxxb (82±10% VEGFxxxb) to predominantly proangiogenic VEGFxxx (65±1% VEGFxxx; P<0.01, Figure 6D). This change in the AAC1 cells was due to an upregulation in the proangiogenic isoforms of VEGF, since total VEGF increased (P<0.01, Table 1) but VEGFxxxb isoforms did not significantly alter. Neither the total VEGF nor the VEGFxxxb expression in 10C cells was significantly altered by hypoxia.

Table 1
VEGF concentrations in transfected cells

Effect of VEGF165b expression on colon cancer growth rates

Prior to injection of the tumour cells into the mice, expression of VEGF isoforms was measured both by western blotting and by ELISA. Vascular endothelial growth factor concentrations of the LS174t human colonic carcinoma cell line transfected to overexpress VEGF165, VEGF165b, VEGF165 and VEGF165b (VEGF165/165b), or with the empty expression vector (pcDNA3) are given in Table 1.

Proliferation of LS174t cells after transfection with VEGF165, VEGF165b, both or control vector was measured by flow cytometry. Histogram analysis of propidium iodide-labelled cells showed that there was no significant difference between the cell cycle stage of the groups (control 79±2.3%, VEGF165 80±3%, VEGF165b 83±5% and VEGF165/165b 77±0.7% in G0/G1; P>0.1). Apoptosis and necrosis were also measured by dual PI/Annexin V staining. There were no significant differences between the four groups (data not shown).

VEGF165b slows LS174t tumour growth in vivo

To determine whether VEGF165b expression by the tumour cells inhibited tumour growth in vivo, LS174t human colon carcinoma cells stably transfected to express VEGF165, VEGF165b, both isoforms (VEGF165+VEGF165b), or a control vector were injected into nude mice. Figure 7A shows that control-transfected cells formed large vascular solid tumours within 15 days. Tumours formed from cells overexpressing VEGF165b were smaller and less vascularised (Figure 7B) and had a softer texture. Comparison of tumour volumes made by caliper measurements in live animals showed that VEGF165b-expressing cells formed significantly smaller tumours than control cells (P<0.01, Figure 7C). Overexpression of VEGF165 in LS174t cells resulted in large, vascular tumours (Figure 7D). However, injection of cells expressing both VEGF165 and VEGF165b resulted in smaller, paler tumours than VEGF165 alone (P<0.001, Figures 7E and F). VEGF165b tumours (0.33±0.22 cm3) were significantly smaller than the VEGF165-expressing tumours (1.61±0.57 cm3; P<0.001) at 15 days. Exponential curve fitting to the tumour growth curves was used to calculate the doubling time of the tumour groups. The mean (95% CI) doubling times for pcDNA3, VEGF165 overexpression and VEGF165/165b overexpression were 2.1 (1.9–2.4), 1.9 (1.9–2.1) and 2.4 (2.2–2.6) days respectively. In comparison, the doubling time for VEGF165b overexpression was 3.0 (2.5–3.6) days, which was statistically significantly different (P<0.001) from the other groups. After excision, tumour sections were stained with haematoxylin and eosin, and areas of necrosis quantified (Figure 7G). VEGF165b-expressing tumours had significantly greater areas of necrosis compared with other groups (Figure 7H; P<0.05 ANOVA).

Figure 7
VEGF165b inhibits colon cancer growth in vivo. (A) A total of 2 × 106 LS174t cells transfected with expression vector pcDNA3 injected subcutaneously into nude mice resulted in tumours after 15 days that were large and bloody (excised tumour inset). ...

Bevacizumab can bind VEGF165b

To determine whether bevacizumab bound VEGF165b, a western blot of recombinant human VEGF165 and VEGF165b was carried out by immunodetection with bevacizumab and secondary antibodies to human IgG (Figure 8A). Bevacizumab appeared to detect efficiently recombinant human VEGF165b. To determine the efficiency of binding, and its affinity for VEGF165b, we carried out Biacore analysis of bevacizumab covalently bound to a surface plasmon resonance sensor. Figure 8B shows the association and disassociation kinetics of VEGF165, and Figure 8C those for VEGF165b across this chip (Figure 8D). The ratio of these two gives the overall affinity (KD). The KD was similar for VEGF165 (2.5 nM) and VEGF165b (6.8 nM).

Figure 8
Bevacizumab binds to VEGF165b. (A) Western blot using bevacizumab as the primary detection antibody. Human recombinant VEGF165b or VEGF165 was run on a denaturing gel at increasing concentrations. Both isoforms were detected by bevacizumab. Biacore analysis ...

VEGF165b inhibits the effect of bevacizumab

To determine whether the effect of bevacizumab on tumour growth was dependent on VEGF165b expression, nude mice were injected with either VEGF165b-transfected LS174t colon cancer cells expressing 95% VEGF165b (n=14), or control LS174t cells expressing 94% VEGF165 (n=12). Twenty-four hours after tumour cell injection, bi-weekly treatment with 50 μg bevacizumab or saline was started, and tumour sizes measured every 3–4 days. Figure 9A shows that bevacizumab significantly inhibited the growth of VEGF165-expressing colon cancer cells (P<0.05) within 15 days. Figure 9B shows that even after 35 days of treatment, bevacizumab had no effect on tumour growth in cells expressing predominantly VEGF165b. To determine whether the effect of bevacizumab on previously established tumours was modified by VEGF165b, cells were injected as before, and tumours allowed to grow to 4 mm in diameter before treatment with bevacizumab as above. Figure 9C shows that bevacizumab inhibited the growth of established tumours compared with saline treatment (P<0.05), whereas Figure 9D shows that it did not affect the growth of VEGF165b-expressing tumours. Figure 9E shows that VEGF165b-expressing tumours grew faster than those not expressing VEGF165b when treated with bevacizumab (P<0.05).

Figure 9
Bevacizumab does not inhibit growth of VEGF165b-expressing tumours. LS174t cells overexpressing VEGF165b or controls were implanted into nude mice, and treated with twice weekly intraperitoneal injection of either saline or 50 μg of bevacizumab. ...

VEGF inhibition is toxic to colonic epithelial cells

VEGF165b is strongly expressed in normal colonic tissue and by AAC1 colonic adenoma cells and has been shown to be cytoprotective in renal epithelial cells. Therefore, the sequestration of VEGF165b by addition of either a specific anti-VEGFxxxb antibody or a more general anti-VEGF antibody could be cytotoxic. To explore this, AAC1 adenoma cells (normally express ~85% of their VEGF as VEGF165b) were treated with either an anti-VEGF165b-specific antibody (R&D Systems, cat no. MAB3045) or bevacizumab at increasing doses for 48 h. Cytotoxicity was measured by assaying supernatant for lactate dehydrogenase. Figure 10A shows that VEGF165b inhibition was toxic to AAC1 cells in a dose-dependent manner, increasing the cytotoxicity by 14.4±1.1-fold (P<0.001). Bevacizumab also significantly increased cytotoxicity 4.9±0.5-fold (P<0.001). A nonspecific IgG (1 mg ml−1) resulted in a modest 2.2±0.25-fold increase in cytotoxicity over baseline in AAC1 cells (P<0.01). Much smaller increases in cytotoxicity were seen when LS174t colonic carcinoma cells were treated with the anti-VEGF165b antibody (4.0±0.35-fold) or bevacizumab (3.2±0.6-fold) (Figure 10B, no increase seen with nonspecific IgG). To confirm that the cytotoxicity effects of anti-VEGF antibodies were due to inhibition of VEGFxxxb, the effects of supplementing the media with rhVEGF165b were measured (Figure 10C). Addition of 40 ng ml−1 rhVEGF165b protein abolished cytotoxicity induced by the VEGF165b antibody (P<0.01, one-way ANOVA).

Figure 10
VEGFxxxb inhibition is cytotoxic to colonic adenoma cells, but less so to colonic carcinoma cells. Confluent colonic adenoma (AAC1) and carcinoma (LS174t) cells were exposed to serum-free media supplemented with either bevacizumab (anti-VEGF) or anti-VEGF ...

To evaluate whether the VEGF165b required for AAC1 cell survival was acting through VEGFR1 or VEGFR2, cells were treated with receptor tyrosine kinase inhibitors to selectively inactivate each of these receptors. Selective inhibition (Glass et al, 2006) of either VEGFR1 (10 nM SU5416) or VEGFR2 (200 nM ZM323881) was not toxic to the AAC1 cells (Figure 10D), but combined inhibition of both receptors induced a significant increase in cytotoxicity (1.8±0.29-fold; P<0.05, one-way ANOVA), an effect that could be rescued by the addition of 100 ng ml−1 of either rhVEGF165 or rhVEGF165b protein.


Vascular endothelial growth factor has been identified in thousands of studies as being altered in tumours, and able to affect tumour growth. VEGF165 was originally identified from tumours and tumour cells, showed angiogenic and propermeability activity and was generated from the sequence now described as exon 8a. In 2002, we described VEGF165b, encoded by an alternative sequence in exon 8 (exon 8b), resulting in a protein of identical length but different amino-acid sequence to that encoded by exon 8a. This different C terminus is also found in other VEGF isoforms, resulting in a family of VEGFxxxb splice variants (Perrin et al, 2005) that is expressed in many normal tissues and mirrors the conventional, angiogenic VEGFxxx isoforms.

VEGF165b is expressed in colonic mucosa

Homodimeric VEGF165b is a competitive antagonist of VEGFR2, binding to it with affinity equal to that of VEGF165 (Woolard et al, 2004). Moreover, VEGF165b is not angiogenic, and can act as an antiangiogenic agent in VEGF-mediated angiogenesis, such as in the eye and in the mesentery (Woolard et al, 2004). We show here that these antiangiogenic isoforms of VEGF are expressed as mRNA and protein in both normal colonic epithelial cells and colonic carcinomas. Not only is their expression dominant in normal colonic epithelium, but also remains relatively constant in the carcinomas. Many previous studies have identified VEGF upregulation in colon carcinomas either without distinguishing between the two families of isoforms or by methods that only detect the proangiogenic isoforms. Previously described total VEGF levels seen in normal and CRC samples are similar to those described here (40 and 220 pg mg−1, respectively (Konno et al, 1998)). However, this is a significant underestimate of total VEGF, as the commercially available ELISAs for VEGF have an affinity for VEGF165b of only 42% compared with VEGF165. Thus, a more accurate estimation of VEGF concentrations in tissues requires a correction for this affinity. Here we show that the measured amount of VEGFxxx, but not VEGFxxxb, is increased in CRC, supporting the idea that there is a proangiogenic switch involving upregulation of both VEGF overall and, crucially, of only the proangiogenic splice variants.

However, our results show that the VEGF165b levels in some tissues (approximately half of the normal samples) exceed those of the total VEGF levels, measured by the pan-VEGF ELISA, even after adjustment for the poor affinity of the pan-ELISA for VEGF165b. There are a number of possible reasons for this difference, although none has been clearly proven, mainly relating to the lack of accuracy of the commercial pan-VEGF ELISA when the VEGFxxxb isoforms are considered. These include (a) endogenous heterodimerisation, (b) other isoforms and (c) interference by other as yet unknown proteins and fats. Endogenous heterodimerisation may yield intermediate forms such as VEGF165b:VEGF165 or VEGF121b:VEGF165b. The affinity of the pan-ELISAs for heterodimers has not yet been shown, but may be intermediate between the two homodimers. If half the VEGF165 is dimerised with VEGF165b, then the true total VEGF value may be still higher. Other isoforms of VEGFxxxb exist (Perrin et al, 2005), but the affinity of the ELISAs for these (particularly the commercially available pan-VEGF ELISA) has not been measured. If the affinity of the commercial pan-VEGF ELISA for VEGF121b or VEGF121 was less than that for VEGF165b or VEGF165, then this would also result in an underestimate of the total VEGF levels. Finally, the soluble splice variant of VEGFR1 (sFlt-1) has been shown to inhibit detection of VEGF in previous commercially available pan-VEGF ELISAs (Maynard et al, 2003). We showed that sFlt-1 does not interfere with the current R&D pan-VEGF ELISA, ruling this out as an explanation for the discrepancy, but other proteins, such as soluble VEGFR2, may affect binding. We show here that VEGFxxxb is localised to the same regions of the colonic mucosa as that previously thought to be for proangiogenic VEGF, the lamina propria (Griga et al, 2002), goblet cells and glandular cells of the mucosa (Griga et al, 1999) and our findings for the pan-VEGF stain are consistent with this. The detection of the same cells by the antibody raised specifically against VEGF165b, as by an antibody to all VEGF isoforms, concurs with our ELISA findings that in normal colonic mucosa it is the VEGFxxxb isoforms that predominate. This has significant implications for interpretation of all previous studies investigating VEGF expression in the colon, not only for tumour studies (Hurwitz et al, 2004), but also for collagenous (Griga et al, 2004) and ischaemic colitides (Okuda et al, 2005).

Antiangiogenic VEGF tumour inhibition

The results here show that VEGF overexpression can alter the rate of human xenografted tumour growth in vivo and moreover that VEGF165b can antagonise the effects of VEGF165, thus confirming the role of the C terminus of VEGF in determining its function and the importance of the ratio of VEGFxxxb to VEGFxxx in the progression of tumour growth. The ability of AAT to inhibit xenografted tumour growth has been demonstrated previously (Kendall and Thomas, 1993; Kim et al, 1993; Kanai et al, 1998; Wildiers et al, 2003). The effectiveness of AAT has translated into the clinic with bevacizumab in the treatment of renal (Yang et al, 2003), breast (Ramaswamy et al, 2006) and CRCs (Hurwitz et al, 2004). Furthermore, the ability of VEGF165b to inhibit VEGF165-mediated angiogenesis in a rat mesenteric and rabbit corneal assay (Woolard et al, 2004) and mouse retinal angiogenesis assay (Konopatskaya et al, 2006) suggests that it may serve as a novel AAT agent. Consistent with this, we show here that the overexpression of VEGF165b in human CRC can inhibit tumour growth in vivo, further supporting the potential role of relative VEGFxxxb downregulation as part of the angiogenic switch in tumour progression. Furthermore, neither VEGF165 nor VEGF165b overexpression alters the in vitro proliferation or apoptosis rates of cells, suggesting that the mechanism of action of VEGF in altering tumour growth rate is not through an autocrine pathway, but likely to be via its known antiangiogenic effects. Furthermore, the antagonistic effects of VEGF165b overexpression on tumour growth when co-overexpressed with the potent proangiogenic VEGF165 and the increased tumour necrosis observed when VEGFxxxb was overexpressed further suggests that VEGF165b inhibits tumour growth through antiangiogenesis.

Bevacizumab binds VEGF165b

Bevacizumab binds to all the conventional isoforms of VEGF (Kim et al, 1992) via an epitope on the common region of the protein family, adjacent to the receptor-binding site (Muller et al, 1997). In CRC, the response to bevacizumab is limited to a small subset of patients, approximately 11–12%, but to date this subset has not been shown to be predictable (Jubb et al, 2006). The results here show that the affinity of bevacizumab was similar for VEGF165 and VEGF165b and concur well with the results by Presta et al (1997). Thus the variability in response to bevacizumab could be explained by VEGFxxxb expression. The relative expression levels of the VEGFxxx isoforms in human colon carcinoma vary from only 27% of the VEGFxxxb isoforms to 60-fold excess, whereas in normal colon, we did not detect excess of VEGFxxx over VEGFxxxb. This can explain why in some patients bevacizumab could be a highly effective antiangiogenic agent – those in which the vast majority of the VEGF in their carcinomas is VEGFxxx (the proangiogenic family), whereas in most, those with significant VEGFxxxb expression, bevacizumab may be less effective. To date, no biomarkers have been identified that can predict response to bevacizumab (Ince et al, 2005; Jubb et al, 2006). The differential response in the LS174t tumours to bevacizumab therapy in mice depending upon VEGF165b-to-VEGF165 ratio shown here is suggestive of its role as a potential biomarker in CRC and possibly other cancers that are responsive to bevacizumab. It remains to be seen whether patients with high levels of VEGF165b respond poorly to bevacizumab, but this needs to be tested.

Vascular endothelial growth factor has been shown to be a survival factor for several carcinoma types, including colon. Transfection of RKO colon cancer cells with short interfering RNA against the coding region of VEGF reduced cell proliferation by 67% (Mulkeen et al, 2006). However, given that normal colonic epithelial cells produce principally VEGFxxxb and the toxicity of blocking VEGFxxxb in AAC1 adenoma cells, the autocrine role, may be predominantly due to VEGFxxxb in colonic epithelial cells, suggesting for the first time a physiologically active role of VEGFxxxb. Furthermore, the general anti-VEGF antibody bevacizumab was also cytotoxic to AAC1 cells, suggesting that bevacizumab could potentially have negative effects on normal colonic epithelium, which expresses high levels of VEGFxxxb. A life-threatening complication of bevacizumab therapy is gastrointestinal perforation, the cause of which is unknown (Hurwitz et al, 2004), but could be due to its effects on survival of normal colonic epithelial cells, as suggested by the results shown here.

In summary, we show here that in normal colonic epithelium, the antiangiogenic isoforms form the majority of VEGF, and VEGF upregulation in CRC is unique to the proangiogenic isoforms. These results indicate that the role of VEGF in the normal function of the colonic mucosa may depend either on the function of VEGFxxxb, which is still unknown, or the effect of the balance between the isoforms. We also show that this switch appears to be an endogenous one to transformation, although environmental cues such as hypoxia can also induce the switch. Furthermore, VEGF165b inhibits both colorectal tumour growth (in a VEGF-dependent manner) and the effect of bevacizumab on that tumour growth. We further show that bevacizumab binds VEGF165b and that VEGF165b is an autocrine survival factor for colonic epithelial cells. These results suggest that anti-VEGF therapy for CRC may be better targeted to patients with significant excess of proangiogenic isoforms over antiangiogenic isoforms, and that therapies that specifically target the proangiogenic isoforms may be more effective.


This work was supported by the Royal College of Surgeons of England (AHRV), Cancer Research UK (AHRV, ER, ABH), The British Heart Foundation BB2000003 (DOB), North Bristol Research Foundation, Specific Cancer Research Fund and the Richard Bright VEGF Research Trust.


  • Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, Harper SJ. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 2002;62:4123–4131. [PubMed]
  • Boehm T, Folkman J, Browder T, O'Reilly M. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390:404–407. [PubMed]
  • Cebe Suarez S, Pieren M, Cariolato L, Arn S, Hoffmann U, Bogucki A, Manlius C, Wood J, Ballmer-Hofer K. A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell Mol Life Sci. 2006;63:2067–2077. [PubMed]
  • Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction. Anal Biochem. 1987;162:156–159. [PubMed]
  • Ellis LM, Takahashi Y, Liu W, Shaheen RM. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist. 2000;5 Suppl 1:11–15. [PubMed]
  • Folkman J. Tumor angiogenesis. Adv Cancer Res. 1985;43:175–203. [PubMed]
  • Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27–31. [PubMed]
  • Glass CA, Harper SJ, Bates DO. The anti-angiogenic VEGF isoform VEGF165b transiently increases hydraulic conductivity, probably through VEGF receptor 1 in vivo. J Physiol. 2006;572:243–257. [PubMed]
  • Griga T, May B, Pfisterer O, Muller KM, Brasch F. Immunohistochemical localization of vascular endothelial growth factor in colonic mucosa of patients with inflammatory bowel disease. Hepatogastroenterology. 2002;49:116–123. [PubMed]
  • Griga T, Tromm A, Schmiegel W, Pfisterer O, Muller KM, Brasch F. Collagenous colitis: implications for the role of vascular endothelial growth factor in repair mechanisms. Eur J Gastroenterol Hepatol. 2004;16:397–402. [PubMed]
  • Griga T, Voigt E, Gretzer B, Brasch F, May B. Increased production of vascular endothelial growth factor by intestinal mucosa of patients with inflammatory bowel disease. Hepatogastroenterology. 1999;46:920–923. [PubMed]
  • Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342. [PubMed]
  • Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz HI, Kabbinavar F, Novotny WF, Hillan KJ, Koeppen H. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst. 2005;97:981–989. [PubMed]
  • Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, Kabbinavar F, Holden SN, Novotny WF, Frantz GD, Hillan KJ, Koeppen H. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol. 2006;24:217–227. [PubMed]
  • Kanai T, Konno H, Tanaka T, Baba M, Matsumoto K, Nakamura S, Yukita A, Asano M, Suzuki H, Baba S. Anti-tumor and anti-metastatic effects of human-vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int J Cancer. 1998;77:933–936. [PubMed]
  • Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA. 1993;90:10705–10709.
  • Kim KJ, Li B, Houck K, Winer J, Ferrara N. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors. 1992;7:53–64. [PubMed]
  • Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841–844. [PubMed]
  • Konno H, Tanaka T, Baba M, Kanai T, Matsumoto K, Kamiya K, Nakamura S, Baba S. Quantitative analysis of vascular endothelial growth factor in colon cancer. Clinical and experimental. Eur Surg Res. 1998;30:273–278. [PubMed]
  • Konopatskaya O, Churchill AJ, Harper SJ, Bates DO, Gardiner TA. VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Mol Vis. 2006;12:626–632. [PubMed]
  • Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, Park KR, Ferrara N, Jain RK, Suit HD, Boucher Y. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 2000;60:5565–5570. [PubMed]
  • Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649–658. [PMC free article] [PubMed]
  • Miller-Kasprzak E, Jagodzinski PP. 5-Aza-2-deoxycytidine increases the expression of anti-angiogenic vascular endothelial growth factor 189b variant in human lung microvascular endothelial cells Biomed Pharmacother 2008. 62(in press)
  • Mulkeen AL, Silva T, Yoo PS, Schmitz JC, Uchio E, Chu E, Cha C. Short interfering RNA-mediated gene silencing of vascular endothelial growth factor: effects on cellular proliferation in colon cancer cells Arch Surg 2006. 141367–374.374discussion 374 [PubMed]
  • Muller YA, Christinger HW, Keyt BA, de Vos AM. The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding. Structure. 1997;5:1325–1338. [PubMed]
  • Okuda T, Azuma T, Ohtani M, Masaki R, Ito Y, Yamazaki Y, Ito S, Kuriyama M. Hypoxia-inducible factor 1 alpha and vascular endothelial growth factor overexpression in ischemic colitis. World J Gastroenterol. 2005;11:1535–1539. [PubMed]
  • Paraskeva C, Finerty S, Powell S. Immortalization of a human colorectal adenoma cell line by continuous in vitro passage: possible involvement of chromosome 1 in tumour progression. Int J Cancer. 1988;41:908–912. [PubMed]
  • Perrin RM, Konopatskaya O, Qiu Y, Harper S, Bates DO, Churchill AJ. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia. 2005;48:2422–2427. [PubMed]
  • Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593–4599. [PubMed]
  • Pritchard-Jones RO, Dunn DB, Qiu Y, Varey AH, Orlando A, Rigby H, Harper SJ, Bates DO. Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma. Br J Cancer. 2007;97:223–230. [PMC free article] [PubMed]
  • Ramaswamy B, Elias AD, Kelbick NT, Dodley A, Morrow M, Hauger M, Allen J, Rhoades C, Kendra K, Chen HX, Eckhardt SG, Shapiro CL. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res. 2006;12:3124–3129. [PubMed]
  • Reinmuth N, Parikh AA, Ahmad SA, Liu W, Stoeltzing O, Fan F, Takeda A, Akagi M, Ellis LM. Biology of angiogenesis in tumors of the gastrointestinal tract. Microsc Res Tech. 2003;60:199–207. [PubMed]
  • Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, Landuyt W, de Bruijn EA, van Oosterom AT. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer. 2003;88:1979–1986. [PMC free article] [PubMed]
  • Williams AC, Harper SJ, Paraskeva C. Neoplastic transformation of a human colonic epithelial cell line: in vitro evidence for the adenoma to carcinoma sequence. Cancer Res. 1990;50:4724–4730. [PubMed]
  • Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO, Cui TG, Sugiono M, Waine E, Perrin R, Foster R, Digby-Bell J, Shields JD, Whittles CE, Mushens RE, Gillatt DA, Ziche M, Harper SJ, Bates DO. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004;64:7822–7835. [PubMed]
  • Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427–434. [PMC free article] [PubMed]
  • Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA. 1996;93:14765–14770.

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK